2024-516586-37-00招募中2 期
Clofarabine Therapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: a Phase 1/2 Dose-Escalation Study
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD)
研究概览
简要总结
To define maximum tolerated dose of Clofarabine in patients with metastatic or locally advanced urothelial carcinoma
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically or cytologically confirmed urothelial carcinoma, radiologically documented metastatic or unresectable locally advanced disease
- •Adequate renal function as indicated by the following laboratory values: Serum creatinine ≤ 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation
- •Adequate cardiac function (NYHA cardiac III-IV excluded)
- •Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment
- •Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
- •Willing and able to provide informed consent
- •Patients who have already received standard treatment and did not benefit from it, or patients who have refused standard therapy
- •Age ≥ 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Absolute neutrophil count (ANC) greater than or equal to 1500
- •White blood cell (WBC) count greater than 3.0
- •Platelets greater than or equal to 100
- •Hemoglobin greater than 9.0 g/dL
- •Adequate hepatobiliary function as indicated by the following laboratory values: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
排除标准
- •Received previous treatment with clofarabine
- •Had prior treatment with a known nephrotoxic drug within 2 weeks of the first dose of study drug, unless the participants had a calculated GFR >30 at 2 time points no <7 days apart during the 2- week period prior to the first dose of study drug
- •Positive human immunodeficiency virus (HIV) test
- •Female patients who are pregnant/breastfeeding
- •Current concomitant chemotherapy, radiation therapy, or immunotherapy
- •Currently participation in other investigational drug studies or having received other investigational drugs within the previous 30 days
- •Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. In particular: a) New York Heart Association classification stage II, III, or IV congestive heart failure; b) Coronary artery disease or arteriosclerotic cardiovascular disease (angina, myocardial infraction) within 3 months of first dose of study drug; c) Any other primary cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia
- •Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- •Any medical condition that requires chronic use of oral high-dose corticosteroids (in excess of 1 mg/kg/day) (low-dose corticosteroid for pre-medication purposes are allowed)
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
- •Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed
- •Had currently active gastrointestinal disease, or prior surgery that might affect the ability of the participants to absorb oral Clofarabine
结局指标
主要结局
Maximum tolerated dose (MTD)
Maximum tolerated dose (MTD)
次要结局
- Objective response (OR) determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Duration of response (DOR) (radiographic)
- Time to progression (radiographic)
- Progression-free survival (PFS)
- Overall survival (OS)
- Treatment-related adverse events evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5.0)
- Pharmacokinetics parameters of Clofarabine including maximum serum concentration (Cmax) and area under the concentration-time curve (AUC)
研究者
Department of Urology
Scientific
Medical University Of Vienna
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Clofarabine therapy in patients with relapsed or refractory acute myeloid leukemiaPatients with AML >40 years of age with untreated relapse or refractory disease after a minimum of one standardinduction therapy.MedDRA version: 14.1Level: LLTClassification code 10060557Term: Acute myelocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022584-35-DEDresden Universtity of Technology
进行中（未招募）
不适用
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - CLARA-DNXEUCTR2009-009457-13-ATErasmus MC28
进行中（未招募）
1 期
This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myeloid leukemia (AML)EUCTR2009-009457-13-DEErasmus MC34
进行中（未招募）
不适用
This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myeloid leukemia (AML)Relapsed/refractory acute myeloid leukemiaMedDRA version: 14.0Level: LLTClassification code 10066638Term: Acute myeloid leukemia progressionSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009457-13-NLErasmus MC28
进行中（未招募）
不适用
A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML - CLARA-DNXRelapsed/refractory acute myeloid leukemiaMedDRA version: 12.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentMedDRA version: 12.0Level: LLTClassification code 10066638Term: Acute myeloid leukemia progressionEUCTR2009-009457-13-CZErasmus MC28